Cardiovascular multi-omics integrates inherited variation with dynamic molecular measurements and carefully curated clinical phenotypes. Its purpose is not to produce the largest possible dataset, but to test whether complementary biological layers improve a prespecified prediction or mechanistic question beyond established clinical models.
Scientific interpretation framework
A clear framework helps visitors distinguish measurement, evidence and responsible translation into care or research.
Evidence level
Each finding is assessed against peer-reviewed literature, professional guidance, analytical validity and the maturity of clinical evidence. Research signals are identified explicitly and are not presented as established care.
Biological and clinical context
Molecular data are interpreted together with phenotype, family history, medicines, imaging, laboratory measurements and population context. No biomarker is meaningful in isolation.
Responsible output
Reports state the method, result, uncertainty, limitations and appropriate next step. Clinically relevant findings require qualified review; research models require validation before use in patient decisions.
Define the clinical question and cohort
The target outcome, prediction horizon, intended population and comparator model must be defined before analysis. Prospective sampling, representative recruitment and adequate event numbers reduce selection bias and unstable estimates.1
Genomics and polygenic architecture
Rare variants may identify high-impact inherited disease, while polygenic scores summarize many common variants of small effect. Both are largely time invariant and must be interpreted with ancestry, family history and phenotype.1
Transcriptomics and regulatory state
RNA profiles capture active cellular programmes but are sensitive to tissue source, cell composition, collection time and acute illness. Bulk, single-cell and spatial approaches answer different biological questions and cannot be treated as interchangeable.1
Proteomics, metabolomics and lipidomics
Circulating proteins, metabolites and lipids provide dynamic information about inflammation, myocardial stress, vascular biology and metabolism. Pre-analytical conditions, platform effects and medication exposure require rigorous control.2
Integration without data leakage
Feature selection, imputation and model tuning must occur within the training data. Nested cross-validation, locked analysis plans and an untouched test set reduce optimistic bias. The contribution of each omic layer should be reported.1
External validation, calibration and fairness
Discrimination alone is insufficient. Models require calibration, decision-curve analysis and subgroup evaluation across sex, age, ancestry, comorbidity and care setting, followed by independent validation in the population where use is proposed.3
Clinical translation and governance
A model should improve a defined decision over accepted risk scores, provide interpretable uncertainty, support versioning and audit, and undergo prospective impact evaluation. Until these requirements are met, output remains research-only and must not determine treatment by itself.3
- Drouard, G. et al. Machine learning strategies for cardiovascular risk factors from multi-omic data. BMC Med. Inform. Decis. Mak. 24, 131 (2024). doi:10.1186/s12911-024-02530-2
- Wang, M. et al. Proteomic analysis of cardiorespiratory fitness for prediction of mortality and multisystem disease risks. Nat. Med. 30, 1557–1569 (2024). doi:10.1038/s41591-024-03039-x
- AI-based multiomics profiling reveals complementary omics contributions to personalized prediction of cardiovascular disease. Nat. Commun. (2026). doi:10.1038/s41467-026-68956-6